FrancophonIA/ELRC3.0 huggingface dataset:
English: The wording regarding pregnancy and immunocompromised patients should read as follows:
Slovenian: Besedilo glede nosečnosti in imunsko oslabelih bolnikov se mora glasiti:
English: In case of inadvertent vaccination of pregnant women with [PRODUCT NAME], this should not be a reason for termination of pregnancy.
Slovenian: V primeru nenamernega cepljenja nosečnice s cepivom [IME CEPIVA] to ne sme biti razlog za prekinitev nosečnosti.
English: Pregnancy should be avoided for 1 month following vaccination.
Slovenian: Ženska ne sme zanositi 1 mesec po cepljenju.
English: These patients should be monitored carefully for signs of parotitis.
Slovenian: Te bolnike je treba pozorno spremljati glede znakov parotitisa.
English: These patients should be monitored carefully for signs of measles, parotitis, rubella and varicella.
Slovenian: Te bolnike je treba pozorno spremljati glede znakov ošpic, parotitisa, rdečk in noric.
English: These patients should be monitored carefully for signs of measles, parotitis and rubella.
Slovenian: Te bolnike je treba pozorno spremljati glede znakov ošpic, parotitisa in rdečk.
English: These patients should be monitored carefully for signs of measles.
Slovenian: Te bolnike je treba pozorno spremljati glede znakov ošpic.
English: In addition, pregnancy should be avoided for 1 month following vaccination.
Slovenian: Poleg tega 1 mesec po cepljenju ne smete zanositi.
English: Immunocompromised patients who have no contraindication for this vaccination (see section 4.3) may not respond as well as immunocompetent subjects, therefore some of these patients may acquire measles in case of contact, despite appropriate vaccine administration.
Slovenian: Pri bolnikih z oslabelo imunostjo, ki nimajo kontraindikacij za cepljenje s tem cepivom (glejte poglavje 4.3), odziv morda ne bo tako dober kot pri imunskokompetentnih osebah.
English: However, fetal damage has not been documented when mumps vaccines have been given to pregnant women.
Slovenian: Vendar pri uporabi cepiva proti mumpsu pri nosečnicah, niso zabeležili poškodb ploda.
English: Therefore, inadvertent vaccination of unknowingly pregnant women with measles, mumps and rubella containing vaccines should not be a reason for termination of pregnancy.
Slovenian: Zato nenamerno cepljenje nosečnice s cepivi, ki vsebujejo viruse ošpic, mumpsa in rdečk, ne sme biti razlog za prekinitev nosečnosti.
English: However, fetal damage has not been documented when measles, mumps, rubella or varicella vaccines have been given to pregnant women.
Slovenian: Vendar pri uporabi cepiva proti ošpicam, mumpsu, rdečkam ali noricam pri nosečnicah, niso zabeležili poškodb ploda.
English: Amendments to be included in the relevant sections of the package leaflet for multivalent measles, mumps and rubella containing vaccines 2.
Slovenian: Popravki, ki morajo biti vključeni v ustrezna poglavja navodila za uporabo za večvalentna cepiva, ki vsebujejo ošpice, mumps in rdečke 2.
English: Amendments to be included in the relevant sections of the package leaflet for monovalent mumps containing vaccines
Slovenian: Popravki, ki morajo biti vključeni v ustrezna poglavja navodila za uporabo za enovalentna cepiva, ki vsebujejo mumps
English: Amendments to be included in the relevant sections of the summary of product characteristics for multivalent measles, mumps and rubella containing vaccines
Slovenian: Popravki, ki morajo biti vključeni v ustrezna poglavja povzetka glavnih značilnosti zdravila za večvalentna cepiva, ki vsebujejo ošpice, mumps in rdečke
English: Amendments to be included in the relevant sections of the summary of product characteristics for monovalent mumps containing vaccines
Slovenian: Popravki, ki morajo biti vključeni v ustrezna poglavja povzetka glavnih značilnosti zdravila za enovalentna cepiva, ki vsebujejo mumps
English: However, fetal damage has not been documented when measles, mumps or rubella vaccines have been given to pregnant women.
Slovenian: Vendar pri uporabi cepiva proti ošpicam, mumpsu ali rdečkam pri nosečnicah, niso zabeležili poškodb ploda.
English: Amendments to be included in the relevant sections of the summary of product characteristics for multivalent measles, mumps, rubella and varicella containing vaccines
Slovenian: Popravki, ki morajo biti vključeni v ustrezna poglavja povzetka glavnih značilnosti zdravila za večvalentna cepiva, ki vsebujejo ošpice, mumps, rdečke in norice
English: Therefore, inadvertent vaccination of unknowingly pregnant women with mumps containing vaccines should not be a reason for termination of pregnancy.
Slovenian: Zato nenamerno cepljenje nosečnice s cepivi, ki vsebujejo virus mumpsa, ne sme biti razlog za prekinitev nosečnosti.
English: Therefore, inadvertent vaccination of unknowingly pregnant women with measles containing vaccines should not be a reason for termination of pregnancy.
Slovenian: Zato nenamerno cepljenje nosečnice s cepivi, ki vsebujejo virus ošpic, ne sme biti razlog za prekinitev nosečnosti.
English: Amendments to be included in the relevant sections of the package leaflet for multivalent measles and rubella containing vaccines
Slovenian: Popravki, ki morajo biti vključeni v ustrezna poglavja navodila za uporabo za večvalentna cepiva, ki vsebujejo ošpice in rdečke
English: Amendments to be included in the relevant sections of the package leaflet for multivalent measles, mumps, rubella and varicella containing vaccines 2.
Slovenian: Popravki, ki morajo biti vključeni v ustrezna poglavja navodila za uporabo za večvalentna cepiva, ki vsebujejo ošpice, mumps, rdečke in norice 2.
English: Annex III Amendments to relevant sections of the summaries of product characteristics and package leaflets
Slovenian: Popravki ustreznih poglavij v povzetku glavnih značilnosti zdravila in navodilu za uporabo
English: However, fetal damage has not been documented when measles vaccines have been given to pregnant women.
Slovenian: Vendar pri uporabi cepiva proti ošpicam pri nosečnicah, niso zabeležili poškodb ploda.
English: Amendments to be included in the relevant sections of the summary of product characteristics for monovalent measles containing vaccines
Slovenian: Popravki, ki morajo biti vključeni v ustrezna poglavja povzetka glavnih značilnosti zdravila za enovalentna cepiva, ki vsebujejo ošpice
English: Amendments to be included in the relevant sections of the summary of product characteristics for multivalent measles and rubella containing vaccines
Slovenian: Popravki, ki morajo biti vključeni v ustrezna poglavja povzetka glavnih značilnosti zdravila za večvalentna cepiva, ki vsebujejo ošpice in rdečke
English: However, fetal damage has not been documented when rubella vaccines have been given to pregnant women.
Slovenian: Vendar pri uporabi cepiva proti noricam pri nosečnicah, niso zabeležili poškodb ploda.
English: However, fetal damage has not been documented when measles or rubella vaccines have been given to pregnant women.
Slovenian: Vendar pri uporabi cepiva proti ošpicam ali rdečkam pri nosečnicah, niso zabeležili poškodb ploda.
English: Amendments to be included in the relevant sections of the package leaflet for monovalent measles containing vaccines
Slovenian: Popravki, ki morajo biti vključeni v ustrezna poglavja navodila za uporabo za enovalentna cepiva, ki vsebujejo ošpice
English: Therefore, inadvertent vaccination of unknowingly pregnant women with measles and rubella containing vaccines should not be a reason for termination of pregnancy.
Slovenian: Zato nenamerno cepljenje nosečnice s cepivi, ki vsebujejo virusa ošpic in rdečk, ne sme biti razlog za prekinitev nosečnosti.
English: Amendments to be included in the relevant sections of the package leaflet for monovalent rubella containing vaccines
Slovenian: Popravki, ki morajo biti vključeni v ustrezna poglavja navodila za uporabo za enovalentna cepiva, ki vsebujejo rdečke
English: Therefore, inadvertent vaccination of unknowingly pregnant women with rubella containing vaccines should not be a reason for termination of pregnancy.
Slovenian: Zato nenamerno cepljenje nosečnice s cepivi, ki vsebujejo virus rdečk, ne sme biti razlog za prekinitev nosečnosti.
English: Amendments to be included in the relevant sections of the summary of product characteristics for monovalent rubella containing vaccines
Slovenian: Popravki, ki morajo biti vključeni v ustrezna poglavja povzetka glavnih značilnosti zdravila za enovalentna cepiva, ki vsebujejo rdečke
English: Further information on Betaferon can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/betaferon.
Slovenian: Nadaljnje informacije o zdravilu Betaferon so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/betaferon.
English: What measures are being taken to ensure the safe and effective use of Betaferon?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Betaferon?
English: In the other study, no delay in the time to disability progression was seen.
Slovenian: V drugi študiji do odloga napredovanja invalidnosti ni prišlo.
English: Other information about Betaferon
Slovenian: Druge informacije o zdravilu Betaferon
English: The European Medicines Agency decided that Betaferon's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Betaferon večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: Betaferon is used in patients:
Slovenian: Zdravilo Betaferon se uporablja pri bolnikih:
English: Betaferon received a marketing authorisation valid throughout the EU on 30 November 1995.
Slovenian: Za zdravilo Betaferon je bilo 30. novembra 1995 izdano dovoljenje za promet, veljavno po vsej EU.
English: Side effects are common at the beginning of treatment but usually decrease with further treatment.
Slovenian: Neželeni učinki so pogosti na začetku zdravljenja, vendar se z nadaljevanjem zdravljenja običajno zmanjšajo.
English: As for all medicines, data on the use of Betaferon are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Betaferon stalno spremljajo.
English: What are the risks associated with Betaferon?
Slovenian: Kakšna tveganja so povezana z zdravilom Betaferon?
English: What benefits of Betaferon have been shown in studies?
Slovenian: Kakšne koristi zdravila Betaferon so se pokazale v študijah?
English: • who have MS of the type known as ‘relapsing-remitting', when the patient has attacks (relapses) between periods with no symptoms (remissions), in patients with at least two relapses within the last two years;
Slovenian: • ki imajo vrsto multiple skleroze, znano kot „recidivno-remitentna“, pri kateri ima bolnik napade (recidive) med obdobji brez simptomov (remisije), in sicer pri bolnikih z vsaj dvema recidivoma v zadnjih dveh letih;
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Betaferon have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Betaferon upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: In both studies, Betaferon showed a reduction (30%) in the number of clinical relapses.
Slovenian: V obeh študijah je zdravilo Betaferon pokazalo (30-odstotno) zmanjšanje števila kliničnih recidivov.
English: • who have experienced the signs of MS for the first time, and these are severe enough to need treatment with injected corticosteroids (anti-inflammatory medicines).
Slovenian: • pri katerih so se znaki multiple skleroze pojavili prvič, pri čemer so ti dovolj resni, da jih je treba zdraviti z injiciranjem kortikosteroidov (protivnetnih zdravil).
English: Why is Betaferon authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Betaferon odobreno v EU?
English: Betaferon must not be used in patients who have severe depression or have thoughts of suicide.
Slovenian: Zdravilo Betaferon se ne sme uporabljati pri bolnikih, ki imajo hudo depresijo ali samomorilne misli.
English: Betaferon treatment should be stopped in patients whose condition does not improve.
Slovenian: Zdravljenje z zdravilom Betaferon je treba prekiniti pri bolnikih, katerih stanje se ne izboljšuje.
English: An overview of Betaferon and why it is authorised in the EU
Slovenian: Pregled zdravila Betaferon in zakaj je odobreno v EU
English: Side effects reported with Betaferon are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Betaferon, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Treatment should start with 62.5 micrograms (a quarter of the dose) every other day, increasing progressively over 19 days to reach the recommended dose of 250 micrograms given every other day.
Slovenian: Zdravljenje je treba začeti z odmerkom 62,5 mikrogramov (četrtina odmerka) vsak drug dan, ki se 19 dni postopoma povečuje, da se doseže priporočeni odmerek 250 mikrogramov vsak drugi dan. Bolniki si lahko po opravljenem ustreznem usposabljanju zdravilo Betaferon injicirajo sami.
English: Betaferon must not be used in patients who have decompensated liver disease (when the liver is damaged and can no longer work adequately).
Slovenian: Ne sme uporabljati pri bolnikih, ki imajo dekompenzirano bolezen jeter (poškodovana jetra, ki ne morejo več ustrezno delovati).
English: For more information about using Betaferon, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Betaferon glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Betaferon is a medicine used to treat adults who have multiple sclerosis (MS).
Slovenian: Betaferon je zdravilo, ki se uporablja za zdravljenje odraslih z multiplo sklerozo (MS).
English: The active substance in Betaferon is the protein interferon beta-1b, one of a group of interferons that can be naturally produced by the body to help it fight against viruses and other attacks.
Slovenian: Učinkovina v zdravilu Betaferon je beljakovina interferon beta-1b, ki je ena od skupin interferonov, ki jih lahko telo naravno ustvari v boju proti virusom in drugim napadom.
English: The most frequent side effects with Betaferon are flu-like symptoms (including fever, chills, joint pain, malaise [feeling unwell], sweating, headache and muscle pain) and reactions at the site of injection.
Slovenian: Najpogostejši neželeni učinki zdravila Betaferon so gripi podobni simptomi (vključno s povišano telesno temperaturo, mrzlico, bolečinami v sklepih, slabim počutjem, potenjem, glavobolom in bolečinami v mišicah) in reakcije na mestu injiciranja.
English: • who have secondary progressive MS (the type of MS that comes after relapsing-remitting MS), when their disease is active.
Slovenian: • s sekundarno progresivno multiplo sklerozo (vrsto multiple skleroze, ki nastopi po recidivnoremitentni multipli sklerozi), če je njihova bolezen aktivna.
English: The exact way that Betaferon works in MS is not yet known but the active substance, interferon beta-1b, seems to calm down the immune system, and prevents relapses of MS.
Slovenian: Natančen način delovanja zdravila Betaferon še ni znan, vendar se zdi, da učinkovina, interferon beta-1b, umirja imunski sistem in preprečuje recidive multiple skleroze.
English: What is Betaferon and what is it used for?
Slovenian: Kaj je zdravilo Betaferon in za kaj se uporablja?
English: In MS, the immune system (the body's natural defences) malfunctions and attacks parts of the central nervous system (the brain, spinal cord and optic nerve [nerve that sends signals from the eye to the brain]), causing inflammation that damages the nerves and the insulation around them.
Slovenian: Pri multipli sklerozi imunski sistem (naravni obrambni mehanizmi telesa) ne deluje pravilno in napada dele osrednjega živčnega sistema (možgane, hrbtenjačo in optični živec [živec, ki pošilja signale od očesa do možganov]), kar povzroča vnetje, ki poškoduje živce in njihovo ovojnico.
English: Betaferon was more effective than placebo in reducing the number of annual relapses: patients receiving the medicine had on average 0.84 relapses a year, when patients on placebo had 1.27.
Slovenian: Zdravilo Betaferon je bilo pri zmanjševanju števila recidivov na leto učinkovitejše od placeba: bolniki, ki so prejemali zdravilo Betaferon, so imeli povprečno 0,84 recidiva na leto, medtem ko so jih bolniki, ki so prejemali placebo, imeli 1,27.
English: It is given by injection under the skin.
Slovenian: Zdravilo se injicira v podkožje.
English: MS is a disease in which inflammation damages the protective insulation around nerves (demyelination) as well as the nerves themselves.
Slovenian: Multipla skleroza je bolezen, pri kateri zaradi vnetja pride do poškodbe zaščitne ovojnice okoli živcev (demielinizacije) in samih živcev.
English: One of the two studies showed a significant delay in the time to disability progression (31% risk reduction due to Betaferon) and in the time to becoming wheelchair bound (39%).
Slovenian: Ena od obeh študij je pokazala znaten odlog napredovanja invalidnosti (31-odstotno zmanjšanje tveganja ob jemanju zdravila Betaferon) in nastopa stopnje invalidnosti, pri kateri bolnik potrebuje invalidski voziček (39 %).
English: Betaferon can only be obtained with a prescription and treatment should be started by a doctor who has experience in the treatment of MS.
Slovenian: Predpisovanje in izdaja zdravila Betaferon je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem multiple skleroze.
English: Betaferon is available as a powder and solvent that are made up into a solution that supplies a dose of 250 micrograms.
Slovenian: Zdravilo Betaferon je na voljo v obliki praška in vehikla za pripravo raztopine, ki vsebuje 250mikrogramski odmerek učinkovine.
English: For the full list of side effects and restrictions with Betaferon, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Betaferon glejte navodilo za uporabo.
English: Betaferon was also studied in 487 patients with a single demyelinating event, who received either Betaferon or placebo for two years.
Slovenian: Zdravilo Betaferon so proučevali tudi pri 487 bolnikih z enim samim demielinezacijskim dogodkom, ki so dve leti prejemali bodisi zdravilo Betaferon bodisi placebo.
English: Betaferon was shown to reduce the risk of developing clinically defined MS: 28% of the patients who received Betaferon developed MS, compared with 45% of those who received placebo.
Slovenian: Zdravilo Betaferon dokazano zmanjšuje tveganje za razvoj klinične multiple skleroze: multipla skleroza se je razvila pri 28 % bolnikov, ki so prejemali zdravilo Betaferon, in pri 45 % bolnikov, ki so prejemali placebo.
English: Betaferon contains the active substance interferon beta-1b.
Slovenian: Zdravilo Betaferon vsebuje učinkovino interferon beta-1b.
English: How is Betaferon used?
Slovenian: Kako se zdravilo Betaferon uporablja?
English: Betaferon has also been studied in 1,657 patients in two studies of secondary progressive MS patients who were able to walk, where it was compared with placebo.
Slovenian: Zdravilo Betaferon so proučevali tudi v dveh študijah sekundarne progresivne multiple skleroze pri 1 657 bolnikih, ki so lahko hodili, in ga primerjali s placebom.
English: Betaferon was studied over a two-year period in 338 patients with relapsing remitting MS who were able to walk unaided, where it was compared with placebo (a dummy treatment).
Slovenian: Zdravilo Betaferon so dve leti proučevali pri 338 bolnikih z recidivno-remitentno multiplo sklerozo, ki so lahko hodili brez pomoči, in ga primerjali s placebom (zdravilom brez učinkovine).
English: Betaferon is used when the patient is considered to be at high risk of developing MS. Before using Betaferon, doctors need to exclude other causes for the symptoms;
Slovenian: Pred uporabo zdravila Betaferon morajo zdravniki izključiti druge možne vzroke za opažene simptome;
English: • an examination to check the nerves in your arms and legs
Slovenian: • pregled živcev v vaših rokah in nogah
English: Take the next capsule at the usual time.
Slovenian: Kapsulo vzemite ob običajnem času.
English: A relevance of these findings to humans cannot be excluded.
Slovenian: Pomembnosti teh ugotovitev za človeka ni mogoče izključiti.
English: You should swallow the whole capsule with a glass of water.
Slovenian: Kapsulo morate pogoltniti celo s kozarcem vode.
English: Prins Bernhardplein 200 1097JB Amsterdam Netherlands
Slovenian: Prins Bernhardplein 200 1097JB Amsterdam Nizozemska
English: • measurement of vitamin B12 levels
Slovenian: • meritev ravni vitamina B12
English: ATC Code: A16AX06
Slovenian: Oznaka ATC: A16AX06.
English: The tremor often disappears without needing to stop the treatment.
Slovenian: Tremor pogosto izgine brez potrebe prekinitve zdravljenja.
English: Hard capsule 84 capsules 84x1 capsules
Slovenian: trda kapsula 84 kapsul 84 x 1 kapsula
English: The greatest prevalence was observed between 6 and 12 months.
Slovenian: Največjo prevalenco so opazili med 6
English: - if you are allergic to miglustat or any of the other ingredients of this medicine (listed in section 6).
Slovenian: - če ste alergični na miglustat ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: Quinto dè Stampi Rozzano (MI)
Slovenian: Quinto de Stampi Rozzano (MI)
English: Thirteen patients discontinued treatment due to an adverse event.
Slovenian: Trinajst bolnikov je zdravljenje zaključilo zaradi neželenega dogodka.
English: A No Observed Effect Level (NOEL) was not established and the effect was not dose dependent.
Slovenian: Ravni brez opaženega učinka (NOEL - No Observed Effect Level) niso ugotovili, učinek ni bil odvisen od odmerka.
English: The apparent volume of distribution of miglustat is 83 L. Miglustat does not bind to plasma proteins.
Slovenian: Navidezni volumen porazdelitve miglustata je 83 l. Miglustat se ne veže na beljakovine v plazmi.
English: Most patients get one or more of these side effects mentioned above, usually at the start of treatment or at intervals during treatment.
Slovenian: Pri večini bolnikov se pojavi eden ali več teh neželenih učinkov, običajno na začetku zdravljenja ali občasno med zdravljenjem.
English: Miglustat Dipharma has negligible influence on the ability to drive and use machines.
Slovenian: Zdravilo Miglustat Dipharma ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
English: • monitoring growth if you are a child or adolescent with Niemann-Pick type C disease
Slovenian: • nadziranje rasti, če ste otrok ali mladostnik z Niemann-Pickovo boleznijo tipa C
English: Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Slovenian: Znotraj vsake pogostnostne skupine so neželeni učinki navedeni po padajoči resnosti.
English: for an average duration of 2.1 years.
Slovenian: Povprečno zdravljenje je trajalo 2.1 leto.
English: 20089 Quinto dè Stampi - Rozzano (MI)
Slovenian: 20089 Quinto dè Stampi - Rozzano (MI) Italija
English: Liver volume (primary efficacy variable) was unchanged from baseline to the end of treatment.
Slovenian: Jetrni volumen (primarna spremenljivka učinkovitosti) se od izhodišča do konca zdravljenja ni spremenil.
English: Among the 41 patients enrolled in the trial 14 patients were treated with miglustat for more than 3 years.
Slovenian: Med 41 bolniki, vključenimi v preskušanje, je bilo 14 bolnikov zdravljenih z zdravilom miglustat več kot 3 leta.
English: The tests will help the doctor decide whether these effects are due to your disease or other existing conditions, or due to side effects of Miglustat Dipharma (see section 4 for further details).
Slovenian: Te preiskave bodo zdravniku v pomoč pri presoji, ali so ti učinki posledica vaše bolezni ali drugega obstoječega stanja ali posledica neželenih učinkov zdravila Miglustat Dipharma (za dodatne informacije glejte poglavje 4).